Clinical Trials Sponsored by Pedram Bral

Total 425 results

Pedram Bral

Completed

Ultrasound Guided Posterior Quadratus Lumborum Block for Postoperative Analgesia in Gynecologic Surgery

Post-operative Pain | Gynecologic Surgery | Regional Anesthesia

United States
Brac

Completed

Presbyopia Screening by Community Health Worker in Bangladesh

Presbyopia
Pedra Technology, PTE LTD

Completed

Improving Radiological Outcomes in Arterial Disease - A Pilot Evaluation of the Pedra Tissue Perfusion Monitoring System (IROAD)

Peripheral Arterial Disease | Chronic Limb Ischemia

United Kingdom
Brac
VisionSpring

Completed

Reading Glass on Livelihoods and Quality of Life in Rural Bangladesh

Presbyopia

Bangladesh
Pedra Technology, PTE LTD

Not yet recruiting

Preliminary Tissue Monitoring During Endovascular Intervention Study (mini-TIME)

Arterial Occlusive Diseases | Peripheral Arterial Disease | Peripheral Artery Disease
BRAC University
Brac; The Behavioural Insights Team

Active, not recruiting

BRAC Institute of Governance and Development-Hygiene Behavioural Change and Coalition ((BIGD-HBCC))

Hygiene Practices and Knowledge

Bangladesh
Philips Oral Healthcare

Completed

Evaluating the Effect of Tooth Cleaning Devices on Oral Health

Dental Plaque

United States
Pedra Technology, PTE LTD

Unknown

Tissue Monitoring During Endovascular Intervention (TIME)

Arterial Occlusive Diseases | Peripheral Arterial Disease | Peripheral Artery Disease
Oral Defense, LLC

Terminated

Effect of Over-the-counter Toothpastes on Chemotherapy-induced Oral Mucositis (TPvsM)

Neoplasms | Mucositis

United States
Philips Oral Healthcare

Completed

Efficacy and Safety Study of Interproximal Cleaning Modalities on Oral Health

Gingivitis

United States
Ural State Medical University
Ural Institute of Cardiology; Ural Federal University; De Haar Research Foundation

Terminated

Plasmonic Photothermal and Stem Cell Therapy of Atherosclerosis Versus Stenting (NANOM PCI)

Coronary Artery Disease | Atherosclerosis

Netherlands, Russian Federation
Petra Pharma

Unknown

A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors

Breast Cancer | Head and Neck Cancer | Lung Cancer | Endometrial Cancer | Colo-rectal Cancer
Bial - Portela C S.A.

Active, not recruiting

eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs. (ADOPTION)

Parkinson Disease

Spain, Italy, Portugal, Germany, United Kingdom
Bial - Portela C S.A.

Completed

Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Sildenafil

Pulmonary Arterial Hypertension

Germany
Bial - Portela C S.A.

Completed

Effect of BIA 5-1058 400 mg on Warfarin Pharmacokinetics

Pulmonary Arterial Hypertension

Germany
Bial - Portela C S.A.

Completed

Relative Bioavailability and Bioequivalence of Opicapone

Parkinson Disease

United Kingdom
Bial - Portela C S.A.

Completed

Effect of BIA 5-1058 on the Steady State Pharmacokinetics of Treprostinil

Pulmonary Arterial Hypertension

Germany
Bial - Portela C S.A.

Completed

Bioavailability and Bioequivalence Study of Two Different Sources of Opicapone

Parkinson Disease

Germany
Bial - Portela C S.A.

Completed

Efficacy and Safety of Opicapone in Clinical Practice (OPTIPARK)

Parkinson's Disease With Wearing-off Motor Fluctuations

Germany
Bial - Portela C S.A.

Completed

Pharmacokinetics, Efficacy and Tolerability of BIA 2-093

Epilepsy

Romania
Bial - Portela C S.A.

Completed

Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly Patients

Epilepsy

Spain, Bulgaria, Austria, Croatia, Czechia, France, Germany, Poland, Portugal, Romania
Bial - Portela C S.A.

Completed

The Tolerability and Effect of Food on the Pharmacokinetics of a Single 800 mg Oral Dose of BIA 2-093

Epilepsy
Bial - Portela C S.A.

Completed

Effect of Food on Opicapone

Parkinson Disease
Bial - Portela C S.A.

Completed

Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Dose Regimens of BIA 5-453

Hypertension

France
Bial - Portela C S.A.

Completed

Pharmacokinetic Profile of BIA 6-512 in Healthy Elderly Subjects Versus Healthy Young Subjects

Parkinson Disease

Germany
Bial - Portela C S.A.

Completed

Pharmacokinetics of Rising Single-doses of BIA 6-512 and Their Effect on the Levodopa Pharmacokinetics

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Pharmacokinetics of BIA 5-453 and Its Metabolites

Hypertension | Chronic Heart Failure

France
Bial - Portela C S.A.

Completed

Bioavailability Study of BIA 5-453

Hypertension | Congestive Heart Failure

France
Bial - Portela C S.A.

Completed

Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Painful Diabetic Neuropathy

Painful Diabetic Neuropathy
Bial - Portela C S.A.

Completed

Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Gliclazide in Healthy Volunteers

Epilepsy

Portugal
Bial - Portela C S.A.

Completed

Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Carbidopa (100/25 mg)

Parkinson's Disease

Portugal
Bial - Portela C S.A.

Completed

Safety, Tolerability, Pharmacokinetic, Including Food Interaction, and Pharmacodynamic Profile of BIA 5-1058.

Hypertension and Chronic Heart Failure

Netherlands
Bial - Portela C S.A.

Completed

Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin

Parkinson's Disease (PD)

Portugal
Bial - Portela C S.A.

Completed

Relative Bioavailability and Bioequivalence Of Different Formulations of Opicapone in Healthy Volunteers

Parkinson
Bial - Portela C S.A.

Completed

Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide

Parkinson Disease

Canada
Bial - Portela C S.A.

Completed

An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and Metabolites

Parkinson's Disease (PD)

Netherlands
Bial - Portela C S.A.

Completed

Single-dose Pharmacokinetics and Relative Bioavailability of Two Different Formulations of Opicapone

Parkinson Disease
Bial - Portela C S.A.

Completed

Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa

Parkinson's Disease (PD)

Canada
Bial - Portela C S.A.

Completed

Pharmacokinetics of BIA 9-1067 and Its Metabolites in Healthy Male Elderly Subjects and in Healthy Male Young Subjects

Parkinson Disease

France
Bial - Portela C S.A.

Completed

An Open-label, Multiple-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093

Epilepsy

South Africa
Bial - Portela C S.A.

Completed

Comparative Bioavailability Study of BIA 9-1067 25 mg Capsules

Parkinson

Canada
Bial - Portela C S.A.

Completed

A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic Profile and CNS Effects of BIA 2-093

Epilepsy

United Kingdom
Bial - Portela C S.A.

Completed

Single-dose Pharmacokinetics and Relative Bioavailability of an Oral Suspension and Two Tablet Formulations of BIA 2-093

Epilepsy

Portugal
Bial - Portela C S.A.

Completed

An Open-label, Single-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093

Epilepsy

South Africa
Bial - Portela C S.A.

Completed

A Study to Evaluate the Tolerability and Pharmacokinetics of Two Single and Multiple High Dose Regimens of BIA 2-093 In Healthy Volunteers

Epilepsy

Portugal
Bial - Portela C S.A.

Completed

A Open-label, Drug Interaction Study Between Eslicarbazepine Acetate and Topiramate

Epilepsy
Bial - Portela C S.A.

Completed

A Sequential Multiple Ascending Dose Study of the Safety and Pharmacokinetics of Eslicarbazepine Acetate in Adult Healthy Volunteers

Epilepsy

United States
Bial - Portela C S.A.

Completed

Effects of Eslicarbazepine Acetate (BIA 2-093) on Cognition and Psychomotor Function

Epilepsy
Bial - Portela C S.A.

Completed

Effect of Opicapone at Steady State on Warfarin Pharmacokinetics

Parkinson's Disease

3

Subscribe